Multiple sclerosis therapy enters phase 2

| Print |  Email
Articles - January 2013
Monday, December 10, 2012

 

BY LINDA BAKER

0113 GamePlan ArtielleMultiple sclerosis is an immune disorder in which the body mistakenly attacks the myelin sheath surrounding nerve fibers in the brain and spinal cord. The resulting neurological symptoms can range from numbness and tingling to paralysis. Although existing therapies reduce inflammation caused by MS, researchers have long sought to develop a therapy that will actually repair the neurological damage.

Enter Artielle ImmunoTherapeutics, a Portland biotech company that will launch an FDA phase-two clinical trial this year for a new therapy researchers say appears to also reverse the dysregulation of the immune system associated with MS and promotes nerve regeneration. The company takes its name from a phonetic rendering of its proprietary technology — recombinant T-cell receptor ligands.

“There is recovery from the disease,” says Arthur Vandenbark, a founding Artielle scientist and a neurology researcher affiliated with the Portland VA Medical Center and Oregon Health & Science University. “That’s what’s so exciting.” The phase-two trial is considered a critical milestone, as it will show the drug can work in MS patients — and not just in animal models. A phase-one trial, indicating the drug’s safety, was completed a few years ago. According to OHSU’s tech-transfer office, Artielle represents the first OHSU drug discovery to be commercialized this far in the clinical trial process by a company that was formed and has remained in Oregon.

Oregon can be a tough environment for homegrown biotech companies, which often struggle to locate investment capital. Founded eight years ago, Artielle is one of the success stories. It has raised $25 million of venture capital, including $2 million from Northwest Technology Ventures and Reference Capital Management, both located in Portland, and $11 million from Sanderling Ventures in the Bay Area, where Artielle CEO Peter McWilliams is based.

The phase-two trial is funded by the Department of Veterans Affairs and will help Artielle achieve its next financial goal: a buyout or partnership with a pharmaceutical company to help bring the product to market.

Only one in about 5,000 biotech startups develops a commercial drug, but the Artielle team thinks they have a shot. The market is saturated with purely anti-inflammatory drugs, says McWilliams. But Artielle’s technology goes further. “This is a disease-modifying agent,” he says.

 

Comments   

 
Guest
0 #1 new ms drugGuest 2013-01-09 19:02:09
what is the main component of the up coming new drug
Quote | Report to administrator
 
 
Guest
-1 #2 infoGuest 2013-02-09 20:49:44
This article gives some info:

http://www.msdiscovery.org/research-resources/drug-pipeline/499-rtl1000

Melanie J
Quote | Report to administrator
 

More Articles

Meeting Facilities Perspective

March 2015
Tuesday, February 24, 2015
BY KIM MOORE | OB RESEARCH EDITOR

A conversation with Donna Earley, director of sales and marketing for the Salem Convention Center.


Read more...

LEED for weed

Linda Baker
Wednesday, January 28, 2015
012815-potcarbon-thumbBY LINDA BAKER | OB EDITOR

What is the impact of the legal pot industry on carbon emissions?


Read more...

Grassroots movement pursues carbon bills

News
Tuesday, February 24, 2015
eventthumbBY KIM MOORE | OB RESEARCH EDITOR

A partnership of a grassroots environmental organization and a youth group is striving to build community and business support for carbon price legislation.


Read more...

MBA Perspective

February 2015
Tuesday, January 27, 2015
BY KIM MOORE

Robin Anderson, dean of the Pamplin School of Business, University of Portland: "You need people who are comfortable leading in ambiguity."


Read more...

Editor's Letter: Tortoise and the Hare

February 2015
Monday, January 26, 2015

The day after this issue goes to press, the city of Medford will host its annual business conference. The event features Minoli Ratnatunga, co-author of the Milken Institute’s annual “Best-Performing Cities” report. Preliminary data suggests that Medford is likely to retain its No. 1 ranking among best-performing small cities for having a higher concentration of high-tech firms than the national average. 


Read more...

Chronicling Gov. Kitzhaber's march to resignation

The Latest
Wednesday, February 11, 2015
021115-kitzhaber-jekaplan14-thumbBY JACOB PALMER | OB DIGITAL NEWS EDITOR

Recapping a wild week featuring plenty of will he or won't he resign drama.


Read more...

Thy neighbor's house

March 2015
Friday, February 20, 2015
BY LINDA BAKER | OB EDITOR

Vacasa may lack the name recognition of Airbnb. But not for long.


Read more...
Oregon Business magazinetitle-sponsored-links-02
SPONSORED LINKS